0QW5 Stock Overview
A biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Heidelberg Pharma AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.27 |
| 52 Week High | €4.00 |
| 52 Week Low | €2.17 |
| Beta | -0.36 |
| 11 Month Change | -9.56% |
| 3 Month Change | -9.20% |
| 1 Year Change | -18.93% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -91.81% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0QW5 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -1.3% | 2.5% | 2.2% |
| 1Y | -18.9% | -15.4% | 9.0% |
Return vs Industry: 0QW5 underperformed the UK Biotechs industry which returned -16.3% over the past year.
Return vs Market: 0QW5 underperformed the UK Market which returned 8.4% over the past year.
Price Volatility
| 0QW5 volatility | |
|---|---|
| 0QW5 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0QW5's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine 0QW5's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 98 | Andreas Pahl | heidelberg-pharma.com |
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. Its lead product candidate is HDP-101, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. The company is developing HDP-102 for the treatment of non-Hodgkin lymphoma; HDP-103, an ATAC candidate to treat metastatic castration-resistant prostate cancer; HDP-104 for the treatment of gastrointestinal tumors.
Heidelberg Pharma AG Fundamentals Summary
| 0QW5 fundamental statistics | |
|---|---|
| Market cap | €105.79m |
| Earnings (TTM) | -€18.77m |
| Revenue (TTM) | €8.47m |
12.5x
P/S Ratio-5.6x
P/E RatioIs 0QW5 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0QW5 income statement (TTM) | |
|---|---|
| Revenue | €8.47m |
| Cost of Revenue | €1.66m |
| Gross Profit | €6.81m |
| Other Expenses | €25.58m |
| Earnings | -€18.77m |
Last Reported Earnings
Aug 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.40 |
| Gross Margin | 80.41% |
| Net Profit Margin | -221.51% |
| Debt/Equity Ratio | 0% |
How did 0QW5 perform over the long term?
See historical performance and comparison